Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics

Richard Becker; Thomas Povsic; Mauricio G. Cohen; Christopher Rusconi; Bruce Sullenger

doi:10.1160/TH09-10-0716

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2010; 103(03): 586-595
DOI: 10.1160/TH09-10-0716

Theme Issue Article

Schattauer GmbH

Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics

Richard Becker

¹Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA

,

Thomas Povsic

²Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA

,

Mauricio G. Cohen

³Miller School of Medicine, University of Miami, Miami, Florida, USA

⁴Cardiac Catheterization Laboratory, University of Miami Hospital, Miami, Florida, USA

,

Christopher Rusconi

⁵Regado Biosciences, Inc, Durham, North Carolina, USA

,

Bruce Sullenger

⁶Department of Genetics, Center for Genetics and Cellular Therapies, Duke University Medical Center, Durham, North Carolina, USA

› Author Affiliations

Abstract

Summary

Antithrombotic therapy for the acute management of thrombotic disorders has been stimulated and guided actively by our current understanding of platelet biology, coagulation proteases, and vascular science. A translatable platform for coagulation, based soundly on biochemistry, enzymology and cellular events on platelets and tissue factor-baring cells, introduces fundamental constructs, mechanistic clarity, and an unparalleled opportunity for accelerating the development and clinical investigation of both disease- and patient-specific therapies. In the current review, we build upon and expand substantially our observations surrounding nucleic acids as antithrombotic agents.

Keywords

Nucleic acids - RNA and DNA aptamers - protein-binding oligonucleotides - anticoagulant therapy

Full Text

References

References
1 Becker RC, Rusconi C, Sullenger B. Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application. Thromb Haemost 2005; 93: 1014-1020.
2 Dausse E. et al. In vitro selection procedures for identifying DNA and RNA aptamers targeted to nucleic acids and proteins. Methods Mol Biol 2005; 288: 391-410.
3 Rimmele M. Nucleic acid aptamers as tools and drugs: recent developments. Chembiochem 2003; 4: 963-971.
4 Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990; 249: 505-510.
5 Dua P, Kim S, Lee DK. Patents on SELEX and therapeutic aptamers. Recent Pat DNA Gene Seq 2008; 2: 172-186.
6 Gopinath SC. Methods developed for SELEX. Anal Bioanal Chem 2007; 387: 171-182.
7 Watrin M. et al. Aptamers targeting RNA molecules. Methods Mol Biol 2009; 535: 79-105.
8 Rusconi CP. et al. Blocking the initiation of coagulation by RNA aptamers to factor VIIa. Thromb Haemost 2000; 84: 841-848.
9 Doudna JA, Cech TR, Sullenger BA. Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor. Proc Natl Acad Sci USA 1995; 92: 2355-2359.
10 Lee SW, Sullenger BA. Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies. Nat Biotechnol 1997; 15: 41-45.
11 Renner S. et al. Maximum common binding modes (MCBM): consensus docking scoring using multiple ligand information and interaction fingerprints. J Chem Inf Model 2008; 48: 319-332.
12 Wu G, Vieth M. SDOCKER: a method utilizing existing X-ray structures to improve docking accuracy. J Med Chem 2004; 47: 3142-3148.
13 Monroe DM. Platelets and Thrombin Generation. Arterioscler Thromb Vasc Biol 2002; 22: 1381-1389.
14 Rusconi CP. et al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 2002; 419: 90-94.
15 Rusconi CP. et al. Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol 2004; 22: 1423-1428.
16 Nimjee SM. et al. A Novel Antidote-Controlled Anticoagulant Reduces Thrombin Generation and Inflammation and Improves Cardiac Function in Cardiopulmonary Bypass Surgery. Mol Ther 2006; 14: 408-415.
17 Tanaka KA. et al. In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry. Thromb Haemost 2009; 101: 827-833.
18 Dyke CK. et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 2006; 114: 2490.
19 Chan MY. et al. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 2008; 117: 2865-2874.
20 Chan MY. et al. A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. J Thromb Haemost 2008; 6: 789-796.
21 Cohen MG. et al. First clinical application of an actively reversible direct factor IXa inhibitor in elective percutaneous coronary intervention. Eur Heart J. 2009 30. 101 (Abstract Supplement)
22 Bock LC. et al. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 1992; 355: 564-566.
23 Griffin LC. et al. In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 1993; 81: 3271-3276.
24 Li WX. et al. A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation. Blood 1994; 83: 677-682.
25 DeAnda Jr A. et al. Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. Ann Thorac Surg 1994; 58: 344-350.
26 Tasset DM, Kubik MF, Steiner W. Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. J Mol Biol 1997; 272: 688-698.
27 Holland CA. et al. Effect of oligodeoxynucleotide thrombin aptamer on thrombin inhibition by heparin cofactor II and antithrombin. FEBS Lett 2000; 484: 87-91.
28 Gatto B. et al. Nucleic acid aptamers based on the G-quadruplex structure: therapeutic and diagnostic potential. Curr Med Chem 2009; 16: 1248-1265.
29 Long SB. et al. Crystal structure of an RNA aptamer bound to thrombin. RNA 2008; 14: 2504-2512.
30 Muller J. et al. Anticoagulant characteristics of HD1–22, a bivalent aptamer that specifically inhibits thrombin and prothrombinase. J Thromb Haemost 2008; 6: 2105-2112.
31 Andrews RK. et al. Glycoprotein Ib-IX-V. Int J Biochem Cell Biol 2003; 35: 1170-1174.
32 Hodivala-Dilke KM. et al. Beta3-integrin-deficient mice are a model for Glanz-mann thrombasthenia showing placental defects and reduced survival. J Clin Invest 1999; 103: 229-238.
33 Smyth SS. et al. Variable protection of beta 3-integrin--deficient mice from thrombosis initiated by different mechanisms. Blood 2001; 98: 1055-1062.
34 Ware J. et al. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc Natl Acad Sci USA 2000; 97: 2803-2808.
35 Oney S. et al. Antidote-Controlled Platelet Inhibition Targeting von Willebrand Factor with Aptamers. Oligonucleotides 2007; 17: 265-274.
36 Gilbert JC. et al. First-in-Human Evaluation of Anti von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy Volunteers. Circulation 2007; 116: 2678-2686.
37 Grossman SA. et al. Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. Neuro Oncol 2005; 7: 32-40.